GRAIL has confirmed that it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. In December 2020, GRAIL completed the enrollment of PATHFINDER, a prospective, 6,600-participant multi-site interventional study conducted under a U.S. Food and Drug Administration Investigational … Continue reading GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test